These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 2125971

  • 1. Thrombolytic effects of tissue-type and urokinase-type plasminogen activators in rabbits with experimental pulmonary thromboembolization.
    Rahman F.
    Fukuoka Igaku Zasshi; 1990 Sep; 81(9):303-12. PubMed ID: 2125971
    [Abstract] [Full Text] [Related]

  • 2. Endotoxin-induced intravascular coagulation in rabbits: effect of tissue plasminogen activator vs urokinase of PAI generation, fibrin deposits and mortality.
    Paloma MJ, Páramo JA, Rocha E.
    Thromb Haemost; 1995 Dec; 74(6):1578-82. PubMed ID: 8772240
    [Abstract] [Full Text] [Related]

  • 3. [New thrombolytic agents in myocardial infarction].
    Charbonnier B, Lang M, Brochier M.
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [Abstract] [Full Text] [Related]

  • 4. [Bolus thrombolysis in pulmonary embolism. Review of experimental and clinical data].
    Zonzin P, Roncon L, Carraro M.
    Ann Ital Med Int; 1996 Nov; 11(2):132-7. PubMed ID: 8974439
    [Abstract] [Full Text] [Related]

  • 5. Synergistic effect on thrombolysis of sequential infusion of tissue-type plasminogen activator (t-PA) single-chain urokinase-type plasminogen activator (scu-PA) and urokinase in the rabbit jugular vein thrombosis model.
    Collen D, Stassen JM, De Cock F.
    Thromb Haemost; 1987 Oct 28; 58(3):943-6. PubMed ID: 3124288
    [Abstract] [Full Text] [Related]

  • 6. Tissue-type plasminogen activator (t-PA) and single chain urokinase-type plasminogen activator (scu-PA): potential for fibrin-specific thrombolytic therapy.
    Collen D.
    Prog Hemost Thromb; 1986 Oct 28; 8():1-18. PubMed ID: 3104986
    [No Abstract] [Full Text] [Related]

  • 7. [Disseminated intravascular coagulation induced by endotoxin in rabbits: effect of treatment with t-PA and urokinase].
    Paloma MJ, Páramo JA, Rifón J, Rocha E.
    Sangre (Barc); 1992 Dec 28; 37(6):435-8. PubMed ID: 1293794
    [Abstract] [Full Text] [Related]

  • 8. Evaluation of fibrinolytic capacity in plasma during thrombolytic therapy with single (scu-PA) or two-chain urokinase type plasminogen activator (tcu-PA) by a combined assay system for urokinase type plasminogen activator antigen and function.
    Wojta J, Binder BR, Huber K, Hoover RL.
    Thromb Haemost; 1989 Apr 25; 61(2):289-93. PubMed ID: 2501899
    [Abstract] [Full Text] [Related]

  • 9. Fibrin-specific thrombolytic agents.
    Collen D.
    Schweiz Med Wochenschr; 1987 Nov 14; 117(46):1791-8. PubMed ID: 3122317
    [Abstract] [Full Text] [Related]

  • 10. [Structure, function and use of fibrinolysis-promoting and inhibiting factors].
    Bachmann F.
    Arzneimittelforschung; 1988 Mar 14; 38(3A):474-8. PubMed ID: 3134901
    [Abstract] [Full Text] [Related]

  • 11. Thrombolytic activity of two chimeric recombinant plasminogen activators (FK2tu-PA and K2tu-PA) in rabbits.
    Agnelli G, Pascucci C, Colucci M, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1992 Sep 07; 68(3):331-5. PubMed ID: 1440500
    [Abstract] [Full Text] [Related]

  • 12. Coronary thrombolysis with clot-selective plasminogen activators.
    Collen D, Bounameaux H.
    Herz; 1986 Feb 07; 11(1):9-15. PubMed ID: 3082731
    [Abstract] [Full Text] [Related]

  • 13. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 14. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM.
    Circulation; 1991 Sep 20; 84(3):1216-34. PubMed ID: 1909220
    [Abstract] [Full Text] [Related]

  • 15. Comparative thrombolytic properties of bolus injections and continuous infusions of a chimeric (t-PA/u-PA) plasminogen activator in a hamster pulmonary embolism model.
    Lu HR, Lijnen HR, Stassen JM, Collen D.
    Blood; 1991 Jul 01; 78(1):125-31. PubMed ID: 1906351
    [Abstract] [Full Text] [Related]

  • 16. A thrombosis model for evaluating thrombolytic agents in the guinea-pig: comparison of t-PA, scu-PA and a novel thrombolytic agent, staphylokinase, on thrombolytic activity.
    Hirata Y, Umemura K, Takiguchi Y, Uematsu T, Nakashima M.
    Blood Coagul Fibrinolysis; 1993 Aug 01; 4(4):569-75. PubMed ID: 7692999
    [Abstract] [Full Text] [Related]

  • 17. Interaction between plasminogen activator inhibitor type 1 (PAI-1) bound to fibrin and either tissue-type plasminogen activator (t-PA) or urokinase-type plasminogen activator (u-PA). Binding of t-PA/PAI-1 complexes to fibrin mediated by both the finger and the kringle-2 domain of t-PA.
    Wagner OF, de Vries C, Hohmann C, Veerman H, Pannekoek H.
    J Clin Invest; 1989 Aug 01; 84(2):647-55. PubMed ID: 2503541
    [Abstract] [Full Text] [Related]

  • 18. Thrombolytic and haemorrhagic effects of bolus doses of tissue-type plasminogen activator and a hybrid plasminogen activator with prolonged plasma half-life (K2tu-PA: CGP 42935).
    Agnelli G, Pascucci C, Nenci GG, Mele A, Bürgi R, Heim J.
    Thromb Haemost; 1993 Aug 02; 70(2):294-300. PubMed ID: 8236138
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.